VRTX Shares Outstanding History
Below is a table of the VRTX shares outstanding history going back to 2/16/2010:

Date VRTX Shares Outstanding
2/16/2010200.58M
4/22/2010202.20M
7/29/2010202.83M
10/21/2010203.19M
2/9/2011204.41M
4/28/2011206.00M
7/29/2011208.09M
10/28/2011208.57M
2/8/2012210.34M
4/27/2012211.06M
7/27/2012215.81M
10/26/2012216.83M
2/15/2013218.19M
4/26/2013221.40M
7/26/2013232.81M
10/31/2013233.76M
2/5/2014235.77M
4/25/2014236.19M
7/25/2014238.08M
10/31/2014240.52M
1/15/2015242.09M
4/24/2015243.75M
7/24/2015244.66M
10/23/2015245.72M
1/31/2016246.39M
4/20/2016247.35M
7/22/2016247.78M
10/21/2016248.03M
2/10/2017248.44M
4/21/2017249.07M
7/21/2017252.12M
10/20/2017252.90M
1/31/2018253.89M
4/20/2018254.83M
7/20/2018255.56M
10/19/2018255.56M
1/31/2019255.66M
4/24/2019256.12M
7/26/2019257.04M
7/25/201917.18M
10/18/2019257.15M

Also see: VRTX Market Cap History
and VRTX YTD Return
VRTX Historical Shares Outstanding:
+2.60% CAGR
VRTX Historical Shares Outstanding: +2.60% CAGR

Mouse over chart for data details
2/16/2010 ...10/18/2019
Vertex Pharmaceuticals is engaged in developing and commercializing therapies for the treatment of cystic fibrosis (CF). Co.'s marketed medicines are SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. Co. is developing VX-150, a NaV1.8 inhibitor, as a potential treatment for pain. Co. is co-developing CTX001, an investigational gene editing treatment, for the treatment of beta-thalassemia and sickle cell disease, with CRISPR Therapeutics AG. We show 41 historical shares outstanding datapoints in our coverage of VRTX's shares outstanding history.

Understanding the changing numbers of VRTX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like VRTX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching VRTX by allowing them to research VRTX shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for VRTX:
VRTX SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Vertex Pharmaceuticals (VRTX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

VRX Shares Outstanding History
VSAR Shares Outstanding History
VSTM Shares Outstanding History
VTGN Shares Outstanding History
VTL Shares Outstanding History
VTVT Shares Outstanding History
VVUS Shares Outstanding History
VYGR Shares Outstanding History
WAT Shares Outstanding History
WCG Shares Outstanding History
More Healthcare companies »

 

VRTX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2019, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.